Recombinant adeno-associated virus (AAV) vectors are predominantly nonintegrating, but rare genomic integration events have been associated with oncogenesis in neonatal murine models. Here we ...
Genethon, the French pioneer in the discovery and development of gene therapies for rare diseases, and Ampersand Biomedicines, a Flagship Pioneering multi-product platform company developing smarter ...
The CHOP's research team findings support the hypothesis that rare AAV integration can contribute to human oncogenesis, which ...
USP recognizes CryoTEM for characterizing empty/full/intermediate capsids on AAV8 reference standards STOCKHOLM, ...
-Oral Presentation at ESGCT Highlights Potential of JCR’s Proprietary JUST-AAV Platform to Facilitate More Efficient Delivery While Reducing Liver Tropism- HYOGO, Japan, October 07, 2025--(BUSINESS ...
Trehalase and NGAL could be strong and consistent independent predictors of ESKD, while β-catenin and IL-18 might be less stable or less predictive.
The development of efficient and safe delivery systems is a cornerstone of gene therapy and genome editing. Lipid nanoparticles (LNPs), adeno-associated ...
Please provide your email address to receive an email when new articles are posted on . A new simulation model can predict a range of clinical outcomes for various therapy strategies in patients with ...
AskBio founder R. Jude Samulski talks about the evolution and future of AAV gene therapy following his company’s blockbuster acquisition by Bayer in 2020. R. Jude Samulski, PhD It is rare that a ...
Genethon, Ampersand Biomedicines partner to design novel AAV vectors with enhanced tissue specificity for effective tolerated gene therapies: France Saturday, May 23, 2026, 16:00 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results